FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia
A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · health
- [HEALTH] Knowledge, Attitudes, and Practices Regarding Arboviruses at a Human-Wildlife Interface: A Cross-Sectional Study in and
- [HEALTH] How to shore up trust during the "cold-period" between pandemics - closing the public trust gap in pandemic preparedness
- [HEALTH] Emergency department evaluation and management of serious and high-risk infections in the febrile returning traveler.
- [HEALTH] Trk1 potassium transport is crucial for effective Candidozyma auris skin colonization.
- [HEALTH] [A rapid visual detection method for porcine circovirus type 4 based on enzymatic recombinase amplification and CRISPR/E
- [HEALTH] [Editorial] The US CDC on the brink